ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,181.60
      -0.43%
      Dow Jones
      39,118.86
      -0.12%
      Brent Oil
      84.85
      0.00%
      Bitcoin
      61,642.82
      1.23%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Five Prime Therapeutics Inc (FPRX)

      7. Five Prime Therapeutics Inc (FPRX) News

      FPRX

      Five Prime Therapeutics (FPRX)

      Five Prime Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:FPRX
      DateTimeSourceHeadlineSymbolCompany
      04/17/20204:10PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FPRXFive Prime Therapeutics Inc
      04/14/20204:38PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FPRXFive Prime Therapeutics Inc
      04/14/20204:29PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:FPRXFive Prime Therapeutics Inc
      04/14/20209:06AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FPRXFive Prime Therapeutics Inc
      04/14/20209:00AMBusiness WireFive Prime Therapeutics Appoints Tom Civik as Chief Executive OfficerNASDAQ:FPRXFive Prime Therapeutics Inc
      04/09/202010:53AMEdgar (US Regulatory)Other FilingNASDAQ:FPRXFive Prime Therapeutics Inc
      04/09/202010:52AMEdgar (US Regulatory)Other FilingNASDAQ:FPRXFive Prime Therapeutics Inc
      04/06/20204:07PMEdgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:FPRXFive Prime Therapeutics Inc
      04/03/20206:10AMEdgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:FPRXFive Prime Therapeutics Inc
      03/23/202012:11PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FPRXFive Prime Therapeutics Inc
      03/20/20203:27PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FPRXFive Prime Therapeutics Inc
      03/13/20209:25AMBusiness WireFive Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical OncologyNASDAQ:FPRXFive Prime Therapeutics Inc
      03/11/20206:33PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FPRXFive Prime Therapeutics Inc
      03/03/20208:36AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FPRXFive Prime Therapeutics Inc
      02/27/20204:18PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FPRXFive Prime Therapeutics Inc
      02/27/20204:05PMBusiness WireFive Prime Therapeutics Reports Fourth Quarter and Full Year 2019 ResultsNASDAQ:FPRXFive Prime Therapeutics Inc
      02/26/20204:07PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FPRXFive Prime Therapeutics Inc
      02/25/20204:22PMBusiness WireFive Prime Therapeutics to Present at Upcoming Healthcare ConferenceNASDAQ:FPRXFive Prime Therapeutics Inc
      02/19/202010:31AMDow Jones NewsFive Prime Therapeutics In License Agreement with Seattle GeneticsNASDAQ:FPRXFive Prime Therapeutics Inc
      02/19/20209:25AMBusiness WireFive Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) ProgramsNASDAQ:FPRXFive Prime Therapeutics Inc
      02/18/202010:35AMDow Jones NewsFive Prime: Phase 2 Cabiralizumab/Opdivo Study Misses EndpointNASDAQ:FPRXFive Prime Therapeutics Inc
      02/18/20209:29AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FPRXFive Prime Therapeutics Inc
      02/18/20209:25AMBusiness WireFive Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic CancerNASDAQ:FPRXFive Prime Therapeutics Inc
      02/14/20204:40PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:FPRXFive Prime Therapeutics Inc
      02/13/20204:05PMBusiness WireFive Prime Therapeutics Announces Timing of Its Fourth Quarter and Full Year 2019 Results Conference CallNASDAQ:FPRXFive Prime Therapeutics Inc
      02/06/20206:52PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FPRXFive Prime Therapeutics Inc
      02/06/20206:49PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FPRXFive Prime Therapeutics Inc
      02/05/202011:48AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:FPRXFive Prime Therapeutics Inc
      01/21/20204:11PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FPRXFive Prime Therapeutics Inc
      01/21/20201:35PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FPRXFive Prime Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:FPRX